92 results about "Immune rejection" patented technology

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The invention discloses application of a 3D hypoxia mesenchymal stem cell derived exosome preparation in preparation of an immune cell proliferation inhibitor or a medicine for treating acute myocardial infarction, belongs to the technical field of biology, and solves the problems of low cell survival rate and immunological rejection in application of a cell treatment method in the prior art. The 3D hypoxia mesenchymal stem cell derived exosome is used as a medium for treating acute myocardial infarction, and the problem of immunological rejection can be solved.

The invention relates to the technical field of biomedical material modification, in particular to a sulfhydrylation biocompatible polymer derivative, a preparation method thereof, extracellular matrix imitating injectable in-situ cross-linked hydrogel and application thereof. According to the invention, a pre-acylation strategy is firstly carried out on the biocompatible polymer containing both amino and carboxyl, so that a three-dimensional cross-linked byproduct formed by coupling of self amido bonds is avoided, meanwhile, the number of side chain carboxyl for sulfhydrylation modification is increased, and the accurate and adjustable pre-acylation rate can optimize the physical and chemical properties of the derivative; meanwhile, a disulfide bond is used as a protective precursor, active sulfydryl is introduced through amido bond coupling, self-oxidation of the active sulfydryl in the reaction process is avoided, sulfydryl activity is guaranteed, hydrazine-containing reagents are avoided, safety is further improved, virus residues and immunological rejection risks are avoided, universality is high, and the application prospect is wide; and in combination with a high-concentration preparation method, the method has the advantage of large-scale production, and further widens the industrial application potential.

The invention relates to hydrogel for promoting healing of diabetic wounds as well as a preparation method and application of the hydrogel, and belongs to the technical field of hydrogel dressings. The invention discloses an exosome hydrogel, which is characterized in that exosome is loaded in crosslinked aldehyde hyaluronic acid and carboxymethyl chitosan, the aldehyde hyaluronic acid is grafted with L-arginine, and the exosome is derived from bone marrow mesenchymal stem cells. L-arginine can release nitric oxide under the action of a diabetic wound surface or an inflammation microenvironment to achieve the effects of resisting bacteria and promoting wound surface recovery, and the exosome successfully avoids the risks of cell survival defects, vascular embolism, immunological rejection and the like while retaining powerful bioactive components. The product has excellent antibacterial activity, degradability, tissue adhesion, injectable performance and self-repairing performance, and can be suitable for wounds in different shapes.

The application belongs to the technical field of biomedical materials, and discloses a collagen-based double-network porous hydrogel scaffold capable of recruiting endogenous stem cells and a construction method and application thereof. The scaffold takes collagen II (Col-II) and oxidized methyl acrylated hyaluronic acid (AHAMA) as an organic phase, and is constructed into a physical / chemical double-network structure through Schiff base dynamic crosslinking and ultraviolet light-induced methacryl radical polymerization. An air-in-water emulsion template method is used to form a through-porous structure, and 5' aldehyde-modified nucleic acid aptamer Apt19S is anchored in the scaffold network to achieve specific recruitment of endogenous pluripotent stem cells. The scaffold has excellent mechanical properties, a biomimetic extracellular matrix microenvironment and a targeted stem cell recruitment function, can effectively promote the directional differentiation of stem cells into chondrocytes, avoids the immune rejection and ethical issues caused by exogenous stem cell transplantation, and is suitable for the field of articular cartilage defect repair.

The invention provides an optimized and far potent chimeric antigen receptor for its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

This invention provides a xenotransplant donor pig that does not express the TEKT5 gene and its preparation method. The TEKT5 gene can cause the risk of xenogeneic immune rejection. The invention also utilizes the CRISPR / Cas9 system to knock out the TEKT5 gene, verifying that the lack of TEKT5 gene expression can effectively reduce the binding ability of donor pig organs, tissues and / or cells to recipient IgG and IgM, improve the ability of donor pig organs, tissues and / or cells to resist recipient complement-mediated cytotoxicity, and prolong the recipient survival time of donor pig organs, tissues and / or pig cells.

The invention particularly relates to a sebastes schlegeli endogenous retrovirus envelope protein percomORF, a lentiviral vector and application of the sebastes schlegeli endogenous retrovirus envelope protein percomORF and the lentiviral vector, and belongs to the field of genetic breeding of molecular biology, and the envelope protein percomORF has an amino acid sequence as shown in SEQ ID NO.1. The invention also covers a membrane fusion protein particle constructed based on the protein, a system for in-vitro assembly of lentivirus particles, a corresponding transformant and a matched kit. By replacing conventional VSVG protein with percomORF protein from sclerobone fish, the infection and transduction efficiency of lentivirus on sclerobone fish cells can be effectively enhanced, and more efficient gene delivery is realized. Besides, the protein belongs to host endogenous Env protein and is beneficial to avoiding immunological rejection caused by introduction of foreign protein, so that the protein has good potential in in-vivo gene delivery application.

The present disclosure provides a recombinant humanized collagen VIII, which is a triple helix structure, has good cell adhesion activity, and is applied to human body without immune rejection and allergic reaction.

The invention relates to the technical field of biological materials, in particular to chitosan-mussel mucin bionic polypeptide-SVF composite hydrogel as well as a preparation method and application thereof. The mussel mucin bionic polypeptide endows the hydrogel with strong adhesion capacity, so that the hydrogel can be firmly adhered to the surface of cartilage, and SVF loss is prevented; as a carrier of the SVF, the hydrogel can be fixed in an articular cavity, the retention time of the hydrogel is prolonged, and the treatment effect is continuously achieved. Chitosan and mussel mucin bionic polypeptide have good biocompatibility and do not cause immunological rejection, an RGD sequence in the polypeptide can promote cell adhesion, chitosan provides a good cell growth microenvironment, and colonization, survival and function exertion of cells in SVF are facilitated. Chitosan has a certain cartilage repair promoting effect and has a synergistic effect with SVF, cartilage regeneration can be more effectively promoted, a hydrogel precursor solution has good fluidity, the hydrogel precursor solution can be injected into an articular cavity in a minimally invasive mode, and operation is easy and convenient.

The application discloses a multifunctional artificial organ device, which comprises a shell, a blood pipe bundle and a hydrogel, the blood pipe bundle is contained in a containing cavity, the blood pipe bundle is communicated with a blood inlet and a blood outlet, the hydrogel is filled in the containing cavity, the hydrogel comprises a gel layer and allogeneic therapeutic cells, the allogeneic therapeutic cells are wrapped in the inside of the gel layer, and the allogeneic therapeutic cells absorb nutrient substances and oxygen separated from the blood pipe bundle and secrete therapeutic factors to the blood pipe bundle. The multifunctional artificial organ device in the embodiment of the application wraps the allogeneic therapeutic cells in the inside of the gel layer, so that the immune rejection of the human body is reduced, the human blood is filtered through the blood pipe bundle, the nutrient substances and oxygen are separated from the blood pipe bundle for normal metabolism of the allogeneic therapeutic cells, the allogeneic therapeutic cells generate therapeutic factors, the therapeutic factors flow to internal organs along with the blood, and the purpose of disease treatment is achieved.

The invention discloses application of keratin in preparation of a bone repair material, and relates to the technical field of biomedical engineering. The preparation method comprises the following steps: extracting bone marrow mesenchymal stem cells, and carrying out osteogenic induction culture under the intervention of keratin with the concentration of 100-800 [mu] g / ml; the culture conditions of the BMSCs are as follows: in a constant-temperature incubator with the temperature of 37 DEG C and 5% CO2, a culture medium contains a precooled complete culture medium; the first liquid changing time of the primary culture of the BMSCs is 48-72 hours, then the liquid is changed once every 2-3 days, and passage is carried out when the cell fusion degree reaches 80%-90%. Keratin is adopted as a natural biological material, has good biocompatibility and biodegradability and can well interact with cells, and immunological rejection is reduced.

The invention discloses application of induced pluripotent stem cell-derived mesenchymal stem cells in preparation of a medicine for treating acute hepatic failure, belongs to the technical field of biomedicine, and solves the problem of unsatisfactory treatment effect caused by immunological rejection when the mesenchymal stem cells are used for treating the acute hepatic failure in the prior art. The induced pluripotent stem cell-derived mesenchymal stem cell provided by the invention has a protective effect on acute liver injury, can improve the levels of aspartate aminotransferase and alanine aminotransferase, remarkably improves the liver function of the injured liver, reduces the level of inflammatory factor TNF-alpha, reduces the necrotic focus area, reduces inflammatory cell infiltration, and has the effects of preventing and treating acute liver injury. The apoptosis level of liver cells is reduced, and the level of CD4 + T cells is reduced.

This invention discloses a co-culture immune isolation device after cell transplantation, belonging to the technical field of cell culture devices. The device includes a culture plate with several first cavities inside and placement slots outside the first cavities. A cover plate is provided above the culture plate, and several second cavities are provided on the cover plate. A sealing ring is provided on the outside of the second cavities, and a liquid inlet mechanism is provided inside the cover plate, connected to the second cavities. This invention uses the above-mentioned co-culture immune isolation device after cell transplantation to achieve co-culture of multiple cells by setting multiple independent first cavities, preventing cell migration or direct contact and avoiding immune rejection. The protective cover and liquid inlet mechanism achieve closed-loop automatic liquid inlet, continuously diffusing signal molecules into the first cavities to maintain co-culture homeostasis and achieve co-culture of multiple cells.

This invention discloses a 3D-printed helical biodegradable anti-inflammatory vascular stent and its preparation method, belonging to the field of vascular stents. The invention uses multiple helical support wires arranged into a tubular shape, with the ends connected in a serpentine transitional manner. The helical support wires are connected by connecting ribs, and the surface is coated. This invention is biodegradable after use, avoiding the harm caused by permanent retention in the body, and has a lower restenosis rate compared to metal stents. The surface of the vascular stent is coated with a spermidine-containing coating to prevent immune rejection of the implanted vascular stent, thereby addressing the problems of inflammation and intimal hyperplasia. The helical structure facilitates contraction and expansion, has good bending flexibility, and the added connecting ribs increase the radial support performance of the vascular stent, better achieving the effect of vascular remodeling. This invention has significant implications in terms of biodegradability, anti-immune rejection, and mechanical properties, and can be used for treatment in different locations such as peripheral and coronary vessels.

This invention discloses a chimeric antigen receptor (CAR), microglia expressing the CAR differentiated from human pluripotent stem cells, and their applications. The chimeric antigen receptor CAR provided by this invention is a bisialic acid ganglioside-based chimeric antigen receptor, and its amino acid sequence is shown in SEQ ID NO.1. This invention also provides a method for preparing microglia expressing the CAR differentiated from human pluripotent stem cells, comprising the following steps: infecting human pluripotent stem cells with the lentivirus; screening for positive clones, selecting positive clones for culture and identification; differentiating the human pluripotent stem cells expressing the CAR into microglia, thereby obtaining the microglia expressing the CAR. The microglia expressing the CAR differentiated from human pluripotent stem cells provided by this invention have unique advantages such as non-immunogenicity and no immune rejection issues in human treatment.

This invention provides transformed cells for the production of transformed replica pigs for xenotransplantation. [Solution] This invention relates to a transformed replica pig from which the heterologous antigens GGTA1, CMAH, iGb3s, β4GalNT2, and β2M genes have been removed from a PERV Envelope C-negative base, and a method for producing the same. The transformed replica pig according to the present invention can overcome hyperacute and antigen-antibody-mediated immune rejection reactions and T-cell-mediated immune rejection reactions without causing the transfer of porcine endogenous retroviruses that occur in xenologous organ transplantation, and can be usefully utilized as a donor animal for interspecies organ and cell transplantation.

The application discloses a kind of bionic immune regulation double-network hydrogel and its preparation method and application, its preparation method is: GelMA-SPD and HAMA-NB are dissolved, join photo-crosslinking agent, crosslinking is carried out under light, obtain double-network hydrogel;GelMA-SPD is methacrylated gelatin-spermidine;HAMA-NB is methacrylated hyaluronic acid N-(2-aminoethyl)-4-[4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy]-butyramide.The hydrogel prepared in the application has good biocompatibility, and the preparation process is simple, and can be degraded.The hydrogel of the application can be applied to tissue repair material or tissue engineering scaffold, and is expected to solve the immune rejection problem in the process of tissue organ transplantation, and is conducive to reducing inflammatory reaction and promoting the rapid healing of tissue trauma.

The invention relates to an anti-immunological rejection FK506 (at) ZIF-8 / HTCC ophthalmic gel and a preparation method thereof, FK506 and a zeolite imidazole skeleton (ZIF-8) are combined to prepare FK506 loaded nanoparticles (FK506 (at) ZIF-8), and quaternized chitosan is innovatively used as a sol of the FK506 (at) ZIF-8 to prepare the ophthalmic gel for use. The problems that a novel potent immune preparation tacrolimus administration mode is short in drug retention time, fast in metabolism, poor in cornea permeability and insoluble in water, and consequently the bioavailability of the FK506 eye drops is low are solved. Compared with an FK506 direct administration mode, the administration mode of the novel nanoparticle drug-loaded ophthalmic gel is higher in drug utilization rate, has a treatment effect on corneal transplantation immunological rejection, and delays the occurrence and development of transplantation rejection.

The invention provides recombinant humanized XXIV type collagen as well as a production method and application thereof, and belongs to the technical field of genetic engineering. The recombinant XXIV type humanized collagen has excellent cell adhesion activity and good biocompatibility, can be used for tissue repair, and does not generate immunological rejection and anaphylactic reaction when applied to a human body.

The invention discloses a rapid breeding method for generating larimichthys crocea sperms based on spermatogonial stem cell transplantation. The rapid breeding method comprises the following steps: step S1, performing whole cryopreservation on larimichthys crocea testis; s2, separating the spermatogonial stem cells of the pseudosciaena crocea; s3, dyeing the spermatogonial stem cells of the pseudosciaena crocea; step S4, treatment of nibea albiflora receptors; and S5, transplanting the dyed donor larimichthys crocea spermatogonial stem cells into the nibea albiflora receptor testis. According to the method, when the nibea albiflora acceptor is treated, the traditional busulfan concentration of 40 mg / kg, twice injection and 35 DEG C high-temperature assistance is optimized into 60 mg / kg, single injection and 22 DEG C normal-temperature culture, optimal parameters induced by busulfan are screened out through experiments, the operation process is simplified under the action of ensuring that endogenous germ cells of the acceptor are reduced and immunological rejection is reduced, and the method is suitable for large-scale popularization and application. The harsh requirement of a high-temperature environment is avoided, and meanwhile the field planting efficiency of donor cells in receptors and the survival rate of the receptors are improved.

The invention provides an application of an exosome in preparation of a medicine for treating syringomyelia. The MSCs-sourced exosome is used for treating syringomyelitis for the first time, and the MSCs-sourced exosome is low in immunogenicity, high in safety and more stable. Therefore, the traditional Chinese medicine composition is easily accepted by patients and is low in cost. And secondly, the exosome is small in size, so that the exosome is conveyed in an intrathecal injection manner, and is not easy to block. Many researches show that the exosome from the MSCs has the effects of protecting nerves and regulating immune microenvironment, can play the same curative effect as the MSCs, has no proliferation ability, no tumorigenicity or immunological rejection risk, and has higher safety than the direct transplantation of the MSCs, so that the exosome better meets the requirements of clinical transformation ethics. Intrathecal exosome injection is expected to become an ideal administration way for treatment of spinal cord diseases such as syringomyelia.

The invention discloses a chimeric receptor with an anti-transplant rejection function and an engineering cell for expressing the chimeric receptor, and further relates to a method for resisting tumors and transplant immunological rejection, in particular to a method for resisting NK cell immunological rejection. The invention also relates to cell therapy.

The invention provides a neural stem cell induced differentiation and clinical application method for intractable epilepsy, and relates to the technical field of biological medicine, the induced differentiation method comprises the following steps: S1, cell source and preparation: adopting induced pluripotent stem cells from a patient; s2, constructing an induced differentiation system, differentiating the induced pluripotent stem cells into GABA (gamma-aminobutyric acid) inhibitory interneurons, and differentiating the GABA inhibitory interneurons; s3, purifying and amplifying the cells, adopting immunomagnetic bead sorting, and purifying and enriching the cells expressing the GABA energy neuron marker; s4, cell quality control; according to the method, the autologous induced pluripotent stem cells of the patient are taken as a source, immunological rejection is avoided, the transplanting safety is improved, and moreover, the high-purity GABAergic neurons can more effectively supplement damaged inhibitory neurons in the brain of the epileptic and reconstruct the inhibition balance of a neural network, so that the epileptic seizure is more effectively controlled.

This invention belongs to the field of genetic engineering technology, specifically relating to a recombinant type I collagen, its preparation method, and its applications. Its amino acid sequence is shown in SEQ ID NO.1. The recombinant type I collagen of this invention is based on a short amino acid sequence from natural type I collagen, with the integrin recognition sequence GFPGER added as a repeating unit, repeated multiple times, with a repetition count of 6. The recombinant type I collagen exhibits extremely good hydrophilicity and stability, high adhesion, and does not cause immune rejection when applied to the human body. It can be used in the preparation of tissue engineering materials such as bone implants and bone repair scaffolds.

The invention provides a method for allele matching of donor mesenchymal stem cells and a receptor. The method comprises the following steps: S10, separating mesenchymal stem cells from perinatal tissue of a donor; s20, extracting genome DNA (deoxyribonucleic acid) of the mesenchymal stem cells, and performing HLA (human leukocyte antigen) genetic typing; s30, performing HLA (human leukocyte antigen) genetic typing on the DNA of the receptor; s40, performing allele spectrum comparison on the HLA gene of the receptor and the HLA gene of the mesenchymal stem cell, and calculating the matching degree; s50, judging the matching degree of the receptor and the mesenchymal stem cells according to the matching degree; and S60, storing the HLA genotyping result of the mesenchymal stem cells and the matching degree in a database, and establishing a matching library for matching the donor mesenchymal stem cells and the receptor. According to the method, a set of standardized system is established, compatibility evaluation of a donor and a receptor at the allele level is achieved, the immunological rejection risk caused by HLA mismatching is effectively predicted and avoided before treatment, and the in-vivo survival and implantation efficiency of MSCs is improved.

The invention provides recombinant humanized XVIII type collagen as well as a production method and application thereof, and belongs to the technical field of biosynthesis. The recombinant XVIII type humanized collagen has excellent cell adhesion activity and good biocompatibility, can be used for tissue repair, and does not generate immunological rejection and anaphylactic reaction when being applied to a human body.

This invention provides a method and application for preparing biological dressings using a combination of enzymes. The preparation method includes static water thawing; dehairing and degreasing; cutting and segmenting; fine trimming and perforation; iodine immersion treatment; purified water immersion treatment; trypsin and neutral protease solution immersion treatment; purified water immersion treatment; antibacterial coating treatment; packaging; and irradiation. This invention significantly improves the antigen removal rate through the combined use of two enzymes. The combined use of these two enzymes enables comprehensive and efficient degradation of different types of heterogeneous proteins, forming a complementary enzymatic process. The combined use of two enzymes can greatly increase the antigen removal rate, significantly improve the biocompatibility of the biological dressing, reduce the risk of immune rejection in clinical applications, and the prepared biological dressing has good biocompatibility and suitable clinical applicability.

The invention relates to the technical field of biological tissue engineering, in particular to a young mesenchymal stem cell-derived apoptotic body as well as a preparation method and application thereof. The apoptotic body is formed by inducing apoptosis of young mesenchymal stem cells through staurosporine. The apoptotic body can reduce the expression level of senescence-related factors and promote expression of matrix synthesis-related factors, so that a degeneration microenvironment is improved, extracellular matrix synthesis is promoted, and cell functions are improved. The apoptotic body can be applied to the field of delaying and reversing intervertebral disc degeneration, promotes repair and regeneration of intervertebral disc tissues by delivering rejuvenation signals, provides a new cell-free treatment strategy for treatment of intervertebral disc degeneration, avoids the risks of low cell survival rate, immunological rejection, tumorigenicity and the like, and has a good application prospect. Meanwhile, the traditional limitation of recovering tissue functions through physical or medicine means is broken through.

This invention relates to the field of biodetection technology, specifically disclosing a multiplex fluorescent staining kit for tissue samples. The kit includes an antibody dissociation buffer, a signal amplification deposition solution, a fluorescent labeling reagent, a tissue-protective imaging medium, and an autofluorescence background inhibitor. This invention utilizes a non-destructive elution technique achieved through the synergistic effect of a low-pH buffer and a directional electric field. It leverages the positively charged nature of antibodies under acidic conditions to drive them away from the tissue and towards the negative electrode, achieving gentle and efficient antibody removal. Simultaneously, it employs a two-step cascade amplification strategy of small molecule deposition and copper-free click chemical labeling, balancing deep penetration with ultra-high sensitivity. This invention can stably support 6-12 cycles of staining, exhibits high elution efficiency, preserves tissue morphology, and can detect low-abundance targets. It is suitable for spatial analysis of the tumor microenvironment, monitoring of transplant immune rejection, and pathological evaluation of neurodegenerative diseases, demonstrating promising clinical application prospects.